The news earlier this week that Siggi Olafsson is leaving Teva, to be succeeded by Dipankar Bhattacharjee (currently head of Teva Generics Europe) comes as something of a surprise, to say the least. As the architect of Teva’s long drawn-out purchase of Allergan’s...
The cuckoo clock ticks for management as Sandoz waits for its biosimilars to make money
At its May ‘Meet the management’ event in Basel, Sandoz was represented by Richard Francis, the MD of the business unit, Peter Goldschmidt, the regional manager for the US and Carol Lynch, head of the biosimilars business. According to Mr Francis, the choice of...
Hartmut Retzlaff falls victim to barbarian hordes
The announcement today that Hartmut Retzlaff has stepped down as CEO of Stada ‘due to a serious long-term illness’ comes as something of a surprise, but the reasons are not hard to discern. For weeks, activist investors in the form of a group called...
Oh My: Mylan, Meda and muddle
Mylan’s announcement last month that it has agreed to buy Meda for $9.9bn was greeted with a distinct lack of enthusiasm by the stock market, which marked the company’s shares down 18% the following day. This was a reversal from the recent norm in...
Into the void: All change in UK generics in 2016
Teva’s announcement last year that it was to acquire Allergan’s generic assets (‘Actavis’), came as a total surprise to the market. All the more so since Teva was, at the time, in hot pursuit of Mylan. It was particularly startling news in the UK,...